A placebo-controlled, randomized, double-blind study of pregnancy and live birth rates after single oral administration of a novel oxytocin antagonist, nolasiban, prior to embryo transfer

H. Tournaye, A. Humberstone, V. Lecomte, P. Terrill, P. Pierzynski, E. Loumaye

ESHRE 33rd Annual Meeting, 2-5 July 2017, Geneva, Switzerland
Abstract O-024: Page i12

Abstracts of the 33rd Annual Meeting of the European Society of Human Reproduction and Embryology, Human Reproduction, Volume 32, Issue suppl_1, July 2017, Pages i1–i539

Combination tocolytics on the inhibition of OT-induced contractions of human pregnant myometrium in vitro

L. Riaposova, S.H. Kim, O. Pohl, A. Chollet, J.P. Gotteland, A. Hanyaloglu, P. Bennett, V. Terzidou

ESHRE 33rd Annual Meeting, 2-5 July 2017, Geneva, Switzerland
Abstract O-119: Page i54

Abstracts of the 33rd Annual Meeting of the European Society of Human Reproduction and Embryology, Human Reproduction, Volume 32, Issue suppl_1, July 2017, Pages i1–i539

FP receptor antagonist, OBE002, inhibits both PGF2α- and OT-induced contractions of human pregnant myometrium in vitro

L. Riaposova, S.H. Kim, O. Pohl, A. Chollet, J.P. Gotteland, A. Hanyaloglu, P. Bennett, V. Terzidou

ESHRE 33rd Annual Meeting, 2-5 July 2017, Geneva, Switzerland
Abstract P-692: Page i452

Abstracts of the 33rd Annual Meeting of the European Society of Human Reproduction and Embryology, Human Reproduction, Volume 32, Issue suppl_1, July 2017, Pages i1–i539

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue